Press Release
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
RPG Life Sciences reported strong Q4 FY26 results with revenue of Rs. 176.9 crores, up 23.6% Y-o-Y, driven by robust Domestic Formulations growth of 18.2% (1.8x market growth) and exceptional API division recovery of 144.3% after the January 2025 fire incident. Full year FY26 revenue stood at Rs. 707.5 crores, an 8.3% increase from Rs. 653.4 crores in FY25. The company maintained healthy EBITDA margins of 25.6% in Q4 and 24.4% for FY26. RPG Life Sciences emerged as the 4th fastest growing pharma company in India, with Domestic Formulations (70% of sales) delivering 13.7% growth vs IPM's 8.6%. The Board recommended a dividend of Rs. 24 per share (300%).
Strong quarterly growth beating market expectations and healthy margins indicate solid operational performance. The API division's recovery from the fire incident removes uncertainty. The generous 300% dividend payout signals confidence in the company's financial health, which could be positive for shareholder returns.